EVFM — Evofem Biosciences, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1618835 ·
Last close
$0.01
Market Cap
$1.06M
52W High
$0.02
52W Low
$0.00
ADV30
181,470
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,633,000 | 2,122,000 | -2,489,000 | -11,036,000 | 7,522,000 | — | 95,038,000 |
| Mar 2026 | 899,000 | 489,000 | -4,569,000 | -5,465,000 | 7,442,000 | 1,491,000 | 85,072,000 |
| Dec 2025 | 9,561,000 | 6,969,000 | 3,345,000 | 2,788,000 | 20,274,000 | — | 94,610,000 |
| Sep 2025 | 4,952,000 | 4,047,000 | -982,000 | -1,569,000 | 13,807,000 | 0 | 88,873,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-251,000
Investing CF
$-7,000
Financing CF
$1,528,000
CapEx
$-5,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-902,875,000
Inventory
$1,890,000
Receivables
$748,000
ST Investments
—
EBIT TTM
$-3,457,000
Pretax Income TTM
$-6,029,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,045,000
EBITDA
$-4,420,000
Free Cash Flow
$6,408,750
Enterprise Value
$60,227,480
Total Cash
$144,000
Total Debt
$54,325,000
Shares Out
132,530,081
Trailing EPS
$-0.11
Book Value
$-0.66
ROE
—
ROA
-26.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 20,183,000 | 1,439,000 | 391,000 | 20,274,000 | 94,610,000 | -74,336,000 | -1,992,000 |
| Dec 2024 | 19,363,000 | -7,676,000 | -8,860,000 | 23,789,000 | 95,046,000 | -71,257,000 | -3,885,000 |
| Dec 2023 | 18,218,000 | -17,847,000 | 52,979,000 | 10,600,000 | 77,100,000 | -66,510,000 | -8,968,000 |
| Dec 2022 | 16,837,000 | -84,124,000 | -76,698,000 | 25,200,000 | 96,963,000 | -71,800,000 | -70,410,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,025,000
NetIncome TTM
$-136,189,000
OpCashFlow TTM
$0
Assets (Latest)
$42,512,000
Forward EPS
$-0.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CDT | CDT Equity Inc. | $1.04M | $0.08 | — |
| SKVI | SKINVISIBLE, INC. | $1.09M | $0.20 | — |
| GSAC | GELSTAT CORP | $1.12M | $0.00 | — |
| CMND | Clearmind Medicine Inc. | $1.17M | $0.79 | — |
| PPCB | Propanc Biopharma, Inc. | $1.22M | $0.53 | — |
News headlines (Yahoo Finance, 1h cache)
Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex
2026-07-23 12:55 · Yahoo
HUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround
2026-07-01 11:00 · Yahoo
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
2025-11-21 14:25 · Yahoo
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
2025-11-13 21:05 · Yahoo
Evofem Announces Voting Results from Special Meeting of Stockholders
2025-10-20 20:18 · Yahoo
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
2025-10-01 12:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.